#16
|
||||
|
||||
Ñëó÷àé èíòåðåñíûé è ïðÿìî ñêàæåì íå òàêîé ÷àñòûé. Ìîæíî êîíå÷íî äåëàòü PFA100 è ñìîòðåòü ê ÷åìó ïàöèåíò ðåçèñòåíòåí. Äóìàþ, ÷òî â âàøåì ñëó÷àå, êîãäà óæå ïðîèçîøåë òðîìáîç, äà åùå íåñêîëêî ðàç âñÿ ïîâåðõíîñòü ñòåíòà èçíóòðè ïðåäñòàâëÿåò ñîáîé ñïëîøíóþ òðîìáîãåííóþ ñóáñòàíöèþ. Îí ó âàñ çàòðîìáèðóåòñÿ ïî âñÿêîìó. Äàæå åñëè âû åãî îòêðîåòå íà ïàäó äíåé, ïàöèåíò ïîëó÷èò Q wave èíôàðêò ÷åðåç ïàðó íåäåëü ñêîðåå âñåãî ñ ëåòàëüíûì èñõîäîì.
Ñêîðåå âñåãî íóæíî ïðèçíàòü ñâîå ôèàñêî è ëå÷èòü ïàöèåíòà îáû÷íûì àñïèðèíîì è âûñîêèìè äîçàìè ñòàòèíîâ â îæèäàíèè ðàçâèòèÿ êîëëàòåðàëåé. Ïîñëå ýòîãî ÷åðåç ïàðó íåäåëü (ìåñÿöåâ) ïîâòîðèòü ñòåññ òåñò ñ SPECT è ïîñìîòðåòü åñòü ëè ñìûñë òóäå âîîáùå åùå ëàçèòü. Åñëè áóäåò ÷òî ñïàñàòü, òî ñäåëàéòå åìó single vessel CABG èç LIMA è âñå. PS: Ïîâûøàòü äîçû êàê àñïèðèíà òàê è ïëàâèêñà ñìûñëà íåò. 75 ìã ïëàâèêñà áëîêèðóåò òî÷íî òàêîåæå êîëè÷åñòâî òðîìáîöèòîâ (îäèíàêîâûé ïóë), ÷òî è 600 ìã. Ðàçíèöà òîëüêî â ñêîðîñòè íàñòóïëåíèÿ ýôôåêòà. |
#17
|
||||
|
||||
Óâàæàåìûé Àëåêñàíäð,
ïî-ìîåìó â Ðîññèþ PFA-100 åùå íå çàâîçèëè, òîëüêî òóðáèäèìåòðè÷. àããðåãàòîìåòðèÿ äîñòóïíà, à ïî÷åìó áû è íå âàðôàðèí? Åùå îäíî îïèñàíèå ïîâòîðíûõ ñòåíò-òðîìáîçîâ è îáíàðóæåííûé äåôèöèò ïðîòåèíà Ñ óñïåøíî êóïèðîâàí âàðôàðèíîì: Int J Cardiovasc Imaging. 2006 Jun-Aug;22(3-4):333-7. Recurrent acute stent thrombosis associated with protein C and S deficiencies.Acar G, Dogan A, Altinbas A, Turker Y. Department of Cardiology, Sevket Demirel Heart Center, Suleyman Demirel University, Isparta, Turkey. Protein C and protein S deficiencies may uncommonly be responsible for coronary arterial thrombosis. We report a young woman with recurrent acute stent thrombosis due to the deficiency of protein C and S. After coronary stenting, stent thrombosis occurred two times despite aggressive antiplatelet therapy, including aspirin, clopidogrel and glycoprotein IIb/IIIa inhibitor. This report suggests that the deficiency of protein C and S should be born in mind in a young patient with recurrent thrombotic events, and that anticoagulants in addition to antiplatelet agents considered in the presence of their deficiency.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#18
|
|||
|
|||
Öèòàòà:
Åñëè ìîæíî ïðèìåðû, à ÿ ñâîè... P.S. Öèòàòà:
|
#19
|
||||
|
||||
Öèòàòà:
Öèòàòà:
Öèòàòà:
Íå âñå òàê î÷åâèäíî. Ýòî çàâèñèò îò ïðè÷èíû ðåçèñòåíòíîñòè. Îíà âïîëíå ìîæåò áûòü íå íà ðåöåïòîðíîì óðîâíå, à, íàïðèìåð, íà ýòàïå îáðàçîâàíèÿ ìåòàáîëèòîâ. Ïðèâåäó êîðîòêóþ öèòàòó èç ïðîñòðàííîãî review: "In recent clinical studies of patients undergoing stenting, a 600 mg clopidogrel loading dose was associated with a higher level of plateletinhibition, lower mean posttreatment reactivity to ADP, and a lower incidence of nonresponsiveness when compared to a 300 mg dose.Moreover, a 600 mg clopidogrel loading dose was associated with a narrower response profile." Vol. 19, No. 5, 2006 Journal of Interventional Cardiology Ïîä÷åðêèâàþ. "higher level of plateletinhibition", à íå ñêîðîñòü íàñòóïëåíèÿ èíãèáèðîâàíèÿ. |
#20
|
||||
|
||||
Öèòàòà:
Öèòàòà:
Öèòàòà:
|
#21
|
||||
|
||||
 ïðèëîæåíèè ê êîíêðåòíîìó ïàöèåíòó òðîìáîç ñëó÷èëñÿ òðèæäû íå ñìîòðÿ íà àäåêâàòíóþ (ìèíóñ 2b3a) òàðàïèþ. Íå äóìàþ, ÷òî åñòü äîñòàòî÷íî äàííûõ, ÷òîáû äîêàçàòåëüíî óòâåðæäàòü ÷òî ñ òàêèì ïàöèåíòîì äåëàòü. ß áû ïðèäåðæèâàëñÿ ïðèíöèïà "íå íàâðåäè". Êñòàòè êàêðòèíêè ìû òàê è íå óâèäåëè. À ÷òî åñëè òàì 65% áûëî? .
|
#22
|
||||
|
||||
Öèòàòà:
|
|
#23
|
|||
|
|||
Öèòàòà:
Ïðè îñòðûõ è ïîäîñòðûõ òðîìáîçàõ % ëåòàëüíîñòè íåñêîëüêî (ðàçà â äâà) ìåíüøå: " Most stent thromboses occurred within the first two days after the procedure, and events after one week were rare. With thrombosis mortality was 19% at one month and 21% at six months" èñòî÷íèê - DE Cutlip et al. Stent thrombosis in the modern era. A pooled analysis of multicentre coronary stent clinical trials. Circulation 2001 103: 1967-1971. ×åì áîëüøå âðåìåíè ïðîøëî ïîñëå ñòåíòèðîâàíèÿ, òåì ìåíüøå âåðîÿòíîñòü ïîëó÷èòü òðîìáîç ñòåíòà (òàê ÷òî ïðîãíîç î Q ÈÌ ÷åðåç ïàðó íåäåëü, íàäåþñü íå îïðàâäàåòñÿ) |
#24
|
||||
|
||||
Öèòàòà:
Öèòàòà:
Öèòàòà:
|
#25
|
||||
|
||||
Öèòàòà:
|
#26
|
|||
|
|||
Îäîáðèòü íå ïîëó÷àåòñÿ (ëèìèò). Ó íàñ òàêæå (ó ñòàáèëüíûõ ïàöèåíòîâ) "ïîñëåäíåå ñëîâî" çà êàðäèîëîãàìè. Ìû ëèøü îáîçíà÷àåì òåõíè÷åñêóþ âîçìîæíîñòü/íåâîçìîæíîñòü è àðãóìåíòû "çà è ïðîòèâ", ïàöèåíò ïîëó÷àåò âñþ èíôîðìàöèþ è ïðèíèìàåò ðåøåíèå (ì.á. ñòðàííî, íî "îòêàçíèêîâ" ìàëî). Áûâàþò àíåêäîòè÷íûå ñèòóàöèè - ïàöèåíò ñ ÎÊÑ (Tr (-)) ïðè ïîñòóïëåíèè îòêàçûâàåòñÿ îò ÊÀÃ, çàòåì èç ÎÐÈÒ ïåðåâîäèòñÿ â ïàëàòó (ñòàáèëüíûé), è íà÷èíàåò òðåáîâàòü êîðîíàðîãðàôèþ, àðãóìåíòèðóÿ, ÷òî ó ñîñåäåé ïî ïàëàòå (ïðàêòè÷åñêè âñåõ) "âåíêè ñåðäöà âèäíû" íà êàðòèíêàõ, à ó íåãî êàðòèíîê íåò (90% ïàöèåíòîâ ïîòîìñòâåííûå ïðîëåòàðèè). Íèêàêèå äîâîäû íå äåéñòâóþò - êàðäèîëîãè ñäàþòñÿ è àêòèâíî "íàâÿëèâàþò" ýòèõ îòêàçíèêîâ íàì, ïðîùå ñäåëàòü, ÷åì îòêàçàòü.
P.S. ÊÀÃ è BMS âñå áåñïëàòíî. |
#27
|
||||
|
||||
Öèòàòà:
|
#28
|
||||
|
||||
 ïðîäîëæåíèå ýòîé òåìû - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
#29
|
|||
|
|||
Ê ñ÷àñòüþ, íà ñåãîäíÿøíèé ìîìåíò ïåññèìèñòè÷åñêèå ïðîãíîçû íå îïðàâäàëèñü. Áîëüíîìó ñäåëàëè êîíòðîëüíóþ ÊÀà è â÷åðà îí áûë âûïèñàí. Èìååò ëè ñìûñë ïðîäëèòü òåðàïèþ ïëàâèêñîì, áîëåå ÷åì 12 ìåñ? È íóæäàåòñÿ ëè îí â òåðàïèè íåïðÿìûìè àíòèêîàãóëÿíòàìè?
|
#30
|
|||
|
|||
|